Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 10;12(11):e0187350.
doi: 10.1371/journal.pone.0187350. eCollection 2017.

Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis

Kaitai Liu  1 , Dawei Zheng  2 , GuoDong Xu  2 , Zhennan Du  3 , Shibo Wu  4
Affiliations

Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis

Kaitai Liu et al. PLoS One. .

Erratum in

Abstract

Patients with stage IV non-small cell lung cancer (NSCLC) comprise a heterogeneous group, and the optimal treatment for this group of patients is complex and debatable. We aimed to assess the effect of local thoracic therapy combined with chemotherapy on cancer specific survival (CSS). To evaluate the CSS of four subgroups of patients with stage IV NSCLC according to four different treatment modalities: combined modality of Chemotherapy, Surgery, and Radiation (Chem+Sur+RT), Chemotherapy and Radiation (Chem+RT), Chemotherapy and Surgery (Chem+Sur), and Chemotherapy only (Chem Only) by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database. Kaplan-Meier methods were adopted and multivariable Cox regression models were built for the analysis of survival outcomes and risk factors. The 3-year CSS was 33.5% in "Chem+Sur+RT" group, 9.3% in "Chem+RT" group, 42.7% in "Chem+Sur" group and 11.8% in "Chem Only" group, which had significant difference in univariate log-rank test (P<0.001) and multivariate Cox regression (P<0.001). Moreover, we observed significant survival benefits in "Chem+Sur" group in all stage of T/N categories, including stage I, stage II, stage IIIa and stage IIIb (all P<0.001). Multimodality therapy, especially combined thoracic surgery and chemotherapy is associated with dramatically improved prognosis for patients with stage IV NSCLC.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Trend of the proportion of stage IV NSCLC patients from 2004 to 2013.
Fig 2
Fig 2. Patterns of care for stage IV NSCLC patients according to treatment modality.
Fig 3
Fig 3. Patterns of care for stage IV NSCLC patients according to stage of T/N.
Fig 4
Fig 4. Survival curves in stage IV NSCLC patients according to different treatment modality.
Fig 5
Fig 5. Survival curves in stage IV NSCLC patients according to treatment modality in stage I of T/N category.
Fig 6
Fig 6. Survival curves in stage IV NSCLC patients according to treatment modality in stage II of T/N category.
Fig 7
Fig 7. Survival curves in stage IV NSCLC patients according to treatment modality in stage IIIa of T/N category.
Fig 8
Fig 8. Survival curves in stage IV NSCLC patients according to treatment modality in stage IIIb of T/N category.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016; 893:1–19. doi: 10.1007/978-3-319-24223-1_1 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017; 67:7–30. doi: 10.3322/caac.21387 - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/.
    1. Cheruvu Praveena, Metcalfe Su K, Metcalfe Justin, Chen Yuhchyau, Okunieff Paul, Milano Michael T. Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol June 2011; 30;6:80 doi: 10.1186/1748-717X-6-80 - DOI - PMC - PubMed
    1. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Rodrigues GB, et al. An individual patient data meta-analysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014; September;15(5):346–55 doi: 10.1016/j.cllc.2014.04.003 - DOI - PubMed